The purchase price has been preliminarily allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows. The allocation as of June 30, 2026 is pending the finalization of the third-party appraisals of intangible assets and corresponding deferred taxes, the finalization of working capital and related account balances, and the lease right-of-use assets and liabilities. There can be no assurance that the estimated amounts recorded as of June 30, 2026 will represent the final purchase price allocation.


(in thousands)
Consideration
Cash	$	4,648,720
Fair value of previously held equity method investment in OneOncology	1,934,224
Estimated contingent consideration	752,141
Settlement of a receivable resulting from a pre-existing commercial relationship	51,990
Estimated fair value of total consideration	$	7,387,075

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents	$	58,891
Accounts receivable	257,823
Inventories	13,177
Prepaid expenses and other	20,628
Property and equipment	482,389
Goodwill	3,873,771
Other intangible assets	3,062,000
Other assets	643,365
Total assets acquired	$	8,412,044

Accounts payable	$	14,772
Accrued expenses and other	192,713
Short-term debt	45,358
Long-term debt	323,985
Deferred income taxes	78,837
Other liabilities	364,386
Total liabilities assumed	$	1,020,051

Net assets acquired	$	7,391,993

Fair value of previously held equity method investment in OneOncology	(1,934,224)
Estimated contingent consideration	(752,141)
Settlement of a receivable resulting from a pre-existing commercial relationship	(51,990)
Noncontrolling interest	(4,918)
Total cash paid	4,648,720
Cash acquired	(58,891)
Net cash paid	$	4,589,829

The Company previously completed the purchase price allocation as of December 31, 2025. The final purchase price has been allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows:


(in thousands)
Consideration
Cash	$	4,042,007
Total estimated contingent consideration	1,087,450
Settlement of a net receivable resulting from a pre-existing commercial relationship	545,738
Estimated fair value of total consideration	$	5,675,195

Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents	$	143,312
Accounts receivable	450,744
Inventories	110,564
Prepaid expenses and other	12,866
Property and equipment	173,098
Goodwill	4,780,042
Other intangible assets	178,000
Deferred income taxes	40,903
Other assets	182,307
Total assets acquired	$	6,071,836

Accounts payable	$	72,385
Accrued expenses and other	163,499
Accrued income taxes	4,258
Other liabilities	156,164
Total liabilities assumed	$	396,306

Net assets acquired	$	5,675,530

Total estimated contingent consideration	(1,087,450)
Settlement of a net receivable resulting from a pre-existing commercial relationship	(545,738)
Noncontrolling interest	(335)
Total cash paid	4,042,007
Cash acquired	(143,312)
Net cash paid	$	3,898,695